Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results Third Quarter Performance Highlights Companion Animal Group ("CAG") CAG revenue growth was led by CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic, including 18% reported and 14% organic gains in International regions, and 8% reported and organic growth in the U.S., outpacing sector growth levels. U.S. growth was aided by increased diagnostic frequency and an easing of clinical visit pressures. Additional U.S. compani ...

Earnings Report - IDEXX Laboratories, Inc. is set to release its third-quarter earnings results on November 3, with analysts expecting earnings of $3.14 per share, an increase from $2.80 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier [1] Recent Performance - On August 4, IDEXX Laboratories reported second-quarter financial results that exceeded expectations and raised its FY25 guidance above estimates [2] - Following the positive report, shares of IDEXX Laboratories rose by 0.2%, closing at $629.51 [2] Analyst Ratings - Stifel analyst Jonathan Block upgraded the stock from Hold to Buy, raising the price target from $640 to $700 [4] - UBS analyst Andrea Alfonso initiated coverage with a Neutral rating and a price target of $720 [4] - Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and raised the price target from $510 to $700 [4] - JP Morgan analyst Chris Scott maintained an Overweight rating and increased the price target from $550 to $675 [4]

Earnings Report - IDEXX Laboratories, Inc. is set to release its third-quarter earnings results on November 3, with analysts expecting earnings of $3.14 per share, an increase from $2.80 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $1.07 billion, compared to $975.54 million a year earlier [1] Recent Performance - On August 4, IDEXX Laboratories reported better-than-expected second-quarter financial results and raised its FY25 guidance above estimates [2] - Following the announcement, shares of IDEXX Laboratories rose 0.2% to close at $629.51 [2] Analyst Ratings - Stifel analyst Jonathan Block upgraded the stock from Hold to Buy, raising the price target from $640 to $700 [4] - UBS analyst Andrea Alfonso initiated coverage with a Neutral rating and a price target of $720 [4] - Morgan Stanley analyst Erin Wright maintained an Overweight rating and increased the price target from $722 to $765 [4] - Piper Sandler analyst David Westenberg maintained a Neutral rating and raised the price target from $510 to $700 [4] - JP Morgan analyst Chris Scott maintained an Overweight rating and increased the price target from $550 to $675 [4]

Earnings Reports - Williams Companies Inc (NYSE:WMB) is expected to report quarterly earnings of 51 cents per share on revenue of $2.89 billion [2] - Spirit AeroSystems Holdings Inc (NYSE:SPR) reported a loss of $4.87 per share with quarterly sales of $1.585 billion, missing the analyst consensus estimate of $1.923 billion [2] - Goodyear Tire & Rubber Co. (NASDAQ:GT) is anticipated to post quarterly earnings of 19 cents per share on revenue of $4.67 billion [2] - IDEXX Laboratories Inc. (NASDAQ:IDXX) is projected to report quarterly earnings of 3.13 per share on revenue of $1.07 billion [2] - ON Semiconductor Corp. (NASDAQ:ON) is expected to post quarterly earnings of 59 cents per share on revenue of $1.51 billion [2] Stock Performance - Williams shares rose 0.4% to close at $57.87 on Friday [2] - Spirit AeroSystems shares gained 1% to close at $36.69 on Friday [2] - Goodyear Tire shares rose 0.6% to $6.93 in after-hours trading [2] - IDEXX Laboratories shares rose 0.9% to $634.89 in after-hours trading [2] - ON Semiconductor shares gained 0.7% to $50.44 in after-hours trading [2]

Core Viewpoint - The article compiles significant research calls from Wall Street, highlighting upgrades for various companies based on their recent performance and outlook. Group 1: Company Upgrades - Jefferies upgraded Apple (AAPL) to Hold from Underperform with a price target of $246.99, up from $203.07, after September quarter revenue grew about 8% and gross margin came in at 47.2%, or about 0.5% better than expected including a $1.1B tariff [2] - Goldman Sachs upgraded Roblox (RBLX) to Buy from Neutral with a price target of $180, up from $155, following the Q3 earnings report, citing strength in bookings, revenue, and daily active user growth, with management optimistic about long-term scaling [2] - BTIG upgraded Unity (U) to Neutral from Sell and removed the prior $27 price target, noting healthy spending trends based on recent surveys of gaming and non-advertising professionals [2] - Piper Sandler upgraded Hershey (HSY) to Neutral from Underweight with an unchanged price target of $167, highlighting the company's plans to be "on-algorithm" in 2026 for better visibility [2] - Stifel upgraded Idexx Laboratories (IDXX) to Buy from Hold with a price target of $700, up from $640, expecting accelerated recurring revenue growth in the Companion Animal Group [2]

Core Viewpoint - Analysts expect Idexx Laboratories (IDXX) to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of 12.1%, with revenues projected at $1.07 billion, up 9.7% from the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.5% in the last 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue Estimates - Revenue from the Companion Animal Group (CAG) is expected to reach $981.37 million, representing a 10% increase from the prior-year quarter [4]. - Revenue from Other segments is projected at $4.48 million, indicating a 1.8% increase year-over-year [4]. - Revenue from Livestock and Poultry Diagnostics (LPD) is estimated at $30.45 million, reflecting a 5% increase from the previous year [5]. - Water revenue is expected to be $54.46 million, showing an 8.6% increase year-over-year [5]. - Revenue from the Companion Animal Group in the United States is projected at $654.89 million, indicating an 8.4% year-over-year change [5]. - International revenue from the Companion Animal Group is estimated at $324.70 million, reflecting a 12.8% increase [6]. - LPD International revenue is expected to be $24.64 million, indicating a 5.1% increase [6]. - Water International revenue is projected at $26.02 million, reflecting a 10.7% increase [6]. Gross Profit Estimates - Gross Profit for the Companion Animal Group (CAG) is expected to reach 61.4%, up from 61.0% reported in the same quarter last year [7]. - Gross Profit for Other segments is projected at 26.2%, compared to 49.9% reported in the previous year [7]. - Gross Profit for LPD is expected to be 50.4%, slightly down from 50.5% reported last year [8]. - Gross Profit for Water is projected at 69.6%, up from 69.3% reported in the same quarter last year [8]. Market Performance - Shares of Idexx have experienced a -0.7% change in the past month, contrasting with a +3.8% move of the Zacks S&P 500 composite [8].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Idexx Laboratories (IDXX) due to higher revenues, with a focus on how actual results will compare to estimates to influence stock price [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.14 per share, reflecting a year-over-year increase of +12.1%, with revenues projected at $1.07 billion, up 9.8% from the previous year [3]. - The earnings report is scheduled for release on November 3, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.46% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.23%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - Idexx has consistently surpassed consensus EPS estimates, achieving this in the last four quarters, including a +9.67% surprise in the most recent quarter [13][14]. Industry Context - In comparison, Edwards Lifesciences (EW) is expected to report earnings of $0.59 per share, indicating a year-over-year decline of -11.9%, with revenues projected at $1.5 billion, up 11.1% from the previous year [18]. - Edwards Lifesciences has a lower Earnings ESP of -1.22% and a Zacks Rank of 3, making it challenging to predict an earnings beat [19].

Core Insights - Conestoga Capital Advisors reported that equity markets reached new all-time highs in Q3 2025, but their Mid Cap Composite underperformed with a return of -3.2% net-of-fees compared to a 2.8% gain for the Russell Midcap Growth Index [1] - The focus on high-quality, profitable companies struggled in a risk-on environment during the quarter [1] Company Overview: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a leader in diagnostics and information systems for veterinary, food, and water testing applications [3] - The company reported a one-month return of -1.74% and a 52-week gain of 38.06%, with shares closing at $637.13 on October 21, 2025, and a market capitalization of $50.97 billion [2] - IDEXX's revenue increased by 11% as reported and 9% organically in Q2 2025, despite weak veterinarian visits [4] Performance and Market Position - IDEXX Laboratories experienced strong earnings in Q3 2025, with accelerated organic revenue growth and rapid adoption of their latest premium instrument [3] - The number of hedge funds holding IDEXX shares decreased from 51 to 48 from the previous quarter, indicating a slight decline in popularity among institutional investors [4]

Core Insights - Hologic (HOLX) and Idexx Laboratories (IDXX) are both considered by investors interested in Medical - Instruments stocks, with a focus on determining which stock is more attractive to value investors [1] Valuation Metrics - Both HOLX and IDXX currently hold a Zacks Rank of 2 (Buy), indicating positive revisions to their earnings estimates and improving earnings outlooks [3] - HOLX has a forward P/E ratio of 16.05, while IDXX has a significantly higher forward P/E of 51.02 [5] - The PEG ratio for HOLX is 2.47, compared to IDXX's PEG ratio of 4.17, suggesting that HOLX may be undervalued relative to its expected earnings growth [5] - HOLX's P/B ratio is 3.3, while IDXX's P/B ratio is 35.29, further indicating that HOLX is more attractively valued [6] - Based on these valuation metrics, HOLX receives a Value grade of B, whereas IDXX receives a Value grade of D, suggesting that HOLX is the superior value option at this time [6]

Core Insights - IDEXX Laboratories, Inc. (IDXX) is scheduled to release its third-quarter 2025 results on November 3, before the market opens, with expectations of strong performance based on previous quarters [1][9] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues is $1.07 billion, reflecting a 9.8% increase from the previous year [2][9] - The Zacks Consensus Estimate for EPS is $3.14, indicating a rise of 12.1% year-over-year [2][9] Performance Drivers - The Companion Animal Group (CAG) is anticipated to significantly contribute to IDEXX's revenue, driven by strong global execution, higher price realization, and increased test volumes [4][9] - The adoption of innovations like the Catalyst Pancreatic Lipase and the IDEXX Cancer Dx diagnostic panel is expected to enhance revenue from CAG Diagnostics [5][9] - Robust placements of premium instruments, particularly the IDEXX inVue Dx Analyzer, are likely to support growth in diagnostic services and accessories [6][9] Segment Performance - CAG business revenues are projected to increase by 10% year-over-year in Q3 2025 [7] - The Water segment is expected to benefit from higher testing volumes in Europe and Asia Pacific, with an estimated 8.6% year-over-year growth [10] - The Livestock, Poultry, and Dairy (LPD) division is forecasted to see a 5% year-over-year increase in revenues, supported by high test volumes and favorable price realization [11] Earnings Expectations - IDEXX Laboratories has an Earnings ESP of +0.23%, indicating a higher likelihood of beating estimates [12] - The company currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [13]